ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

376

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Exudative Age-Related Macular Degeneration

Interventions

BIOLOGICAL

ESBA1008 solution

Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)

BIOLOGICAL

Ranibizumab 0.5 mg

Administered as a single intravitreal injection